Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T-cell-engaging bispecific antibodies in cancer
Niels W.C.J. van de Donk, Sonja Zweegman
The Lancet (2023) Vol. 402, Iss. 10396, pp. 142-158
Closed Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Immunotherapy: a promising approach for glioma treatment
Feroza Yasinjan, Xing Yang, Huayue Geng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 84
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Antonio Tapia‐Galisteo, Luis Álvarez‐Vallina, Laura Sanz
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 56
Translating B cell immunology to the treatment of antibody-mediated allograft rejection
Peter S. Heeger, Maria Carrera Haro, Stanley C. Jordan
Nature Reviews Nephrology (2024) Vol. 20, Iss. 4, pp. 218-232
Closed Access | Times Cited: 26
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 20
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Won Seog Kim, Tae Min Kim, Seok‐Goo Cho, et al.
Nature Cancer (2025)
Closed Access | Times Cited: 3
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Joshua Brody, Judit Jørgensen, David Belada, et al.
Blood (2025)
Open Access | Times Cited: 2
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos, et al.
Blood Advances (2023) Vol. 8, Iss. 1, pp. 194-206
Open Access | Times Cited: 33
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study
Ajay K. Nooka, Cesar Rodriguez, María‐Victoria Mateos, et al.
Cancer (2023) Vol. 130, Iss. 6, pp. 886-900
Open Access | Times Cited: 32
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Peng Ouyang, Lijuan Wang, Jianlong Wu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 16
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
Christie P.M. Verkleij, Chloe O’Neill, Marloes E.C. Broekmans, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 14, pp. 3006-3022
Closed Access | Times Cited: 15
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 15
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2653-2662
Open Access | Times Cited: 12
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
Kaili Zhu, Fei Su, Jingru Yang, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Open Access | Times Cited: 10
Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies
Azra Borogovac, Tanya Siddiqi
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 119-130
Closed Access | Times Cited: 9
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
Linyan Cheng, Lujun Chen, Yuan Shi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
Arthur Géraud, Thomas Hueso, Ariane Laparra, et al.
European Journal of Cancer (2024) Vol. 205, pp. 114075-114075
Closed Access | Times Cited: 9
Hydrophilic biomaterials: From crosslinked and self-assembled hydrogels to polymer-drug conjugates and drug-free macromolecular therapeutics
Jindřich Kopeček
Journal of Controlled Release (2024) Vol. 373, pp. 1-22
Closed Access | Times Cited: 9
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6
Christiane Stadler, Ursula Ellinghaus, Leyla Fischer, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 748
Open Access | Times Cited: 9
Mechanisms of resistance to bispecific T cell engagers in multiple myeloma and their clinical implications
Éric Letouzé, Philippe Moreau, Nikhil Munshi, et al.
Blood Advances (2024) Vol. 8, Iss. 11, pp. 2952-2959
Open Access | Times Cited: 8
Advances in Cell and Immune Therapies for Melanoma
Tanase Timis, Sanda Buruiana, Delia Dima, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 98-98
Open Access | Times Cited: 1
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access | Times Cited: 1
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
Niels W.C.J. van de Donk, Chloe O’Neill, Maaike E. M. de Ruijter, et al.
Current Opinion in Oncology (2023) Vol. 35, Iss. 6, pp. 601-611
Open Access | Times Cited: 19
Elranatamab: First Approval
Sohita Dhillon
Drugs (2023) Vol. 83, Iss. 17, pp. 1621-1627
Closed Access | Times Cited: 18
Bispecific Antibodies in Hematological Malignancies: A Scoping Review
Mohamed H. Omer, Areez Shafqat, Omar Ahmad, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4550-4550
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top